

DAFTAR PUSTAKA

- [1] World Health Organization, "Cancer." <https://www.who.int/health-topics/cancer> (accessed Feb. 20, 2023).
- [2] International Agency for Research on Cancer WHO, "Cancer Today." <https://gco.iarc.fr/today/home> (accessed Feb. 20, 2023).
- [3] Asep Kuswandi, Nisa Habibah Kuswandi, Muslim Kasim, Tan'im, and Mardheni Wulandari, "Karakteristik Histopatologi dan Stadium Klinis Kanker Nasofaring," *Jurnal Ilmiah Kesehatan Sandi Husada*, vol. 1, no. 1, pp. 243–251, 2020.
- [4] Edgar David Sigarlaki, Mukhlis Imanto, and Eka Cania, "Tatalaksana Radioterapi pada Karsinoma Nasofaring," *Medula*, vol. 8, no. 2, pp. 23–26, 2019.
- [5] R. H. Hardiati, C. Nabila, and U. N. Milenia, "Klasifikasi, Faktor Risiko, Tatalaksana dan Komplikasi Kanker Nasofaring," *Jurnal Ilmiah Universitas Batanghari Jambi*, vol. 22, no. 1, pp. 304–307, Feb. 2022, doi: 10.33087/jiubj.v22i1.1780.
- [6] R. Maghri Jodie and S. Rahman, "Gambaran Terapi dan Respon Terapi Karsinoma Nasofaring di RSUP Dr. M. Djamil Padang," 2021.
- [7] K K Fu, "Combined radiotherapy and chemotherapy for nasopharyngeal carcinoma," *Semin Radiat Oncol*, vol. 8, no. 4, pp. 247–253, 1998.
- [8] American Cancer Society, "Chemotherapy Side Effects," May 01, 2020. <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html> (accessed Feb. 28, 2023).
- [9] F. O. Stephens and Karl R. Aigner, *Basics of Oncology*, 1st ed. Heidelberg: Springer Berlin, 2009.
- [10] X. Cheng, F. Li, and L. Liang, "Boron Neutron Capture Therapy: Clinical Application and Research Progress," *Current Oncology*, vol. 29, no. 10. MDPI, pp. 7868–7886, Oct. 01, 2022. doi: 10.3390/currenocol29100622.
- [11] I. Made Ardana and Y. Sardjono, "Optimization Of Collimator Design For BNCT Based Cyclotron 30 Mev And Its Dosimetry Simulation In Head And Neck Soft Tissue Sarcoma Using Monte Carlo N Particle X Program Radiation Protection for Aircrew View project



- measurement of spatial resolution of CT machine View project I Made Ardana Optimization Of Collimator Design For Bnct Based Cyclotron 30 Mev And Its Dosimetry Simulation In Head And Neck Soft Tissue Sarcoma Using Monte Carlo N Particle X Program,” *Proceedings of International Symposium on BNCT*, 2015, [Online]. Available: <https://www.researchgate.net/publication/288380457>
- [12] E. B. Podgorsak, *Radiation Oncology Physics: A Handbook for Teachers and Students*. Vienna: IAEA, 2005.
 - [13] T. Sato, Y. Iwamoto, S. Hashimoto, T. Ogawa, T. Furuta, S. Abe, T. Kai, *Particle and Heavy Ion Transport code System User's Manual Ver. 3.29*. 2022.
 - [14] H. Koivunoro, L. Kankaanranta, T. Seppälä, A. Haapaniemi, A. Mäkitie, and H. Joensuu, “Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival,” *Radiotherapy and Oncology*, vol. 137, pp. 153–158, Aug. 2019, doi: 10.1016/J.RADONC.2019.04.033.
 - [15] R.-T. Chiang, “Analysis of Radiation Interactions and Biological Effects for Boron Neutron Capture Therapy,” *ASEAN Journal on Science and Technology for Development*, vol. 35, no. 3, pp. 203–207, Dec. 2018, doi: 10.29037/AJSTD.535.
 - [16] N. Hu, H. Tanaka, R. Kakino, S. Yoshikawa, M. Miyao, K. Akita, “Improvement in the neutron beam collimation for application in boron neutron capture therapy of the head and neck region,” *Scientific Reports 2022 12:1*, vol. 12, no. 1, pp. 1–12, Aug. 2022, doi: 10.1038/s41598-022-17974-7.
 - [17] N. Hu, H. Tanaka, T. Takata, S. Endo, S. Masunaga, “Evaluation of PHITS for microdosimetry in BNCT to support radiobiological research,” *Applied Radiation and Isotopes*, vol. 161, p. 109148, Jul. 2020, doi: 10.1016/J.APRADISO.2020.109148.
 - [18] Y. S. Yeom, M. C. Han, C. Choi, H. Han, B. Shin, T. Furuta, “Computation Speeds and Memory Requirements of Mesh-Type ICRP Reference Computational Phantoms in Geant4, MCNP6, and PHITS,” *Health Phys*, vol. 116, no. 5, pp. 664–676, May 2019, doi: 10.1097/HP.0000000000000999.
 - [19] Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/684/2019, *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Nasofaring*. 2019.



- [20] Y. Iguchi, H. Michiue, M. Kitamatsu, Y. Hayashi, "Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model," *Biomaterials*, vol. 56, pp. 10–17, Jul. 2015, doi: 10.1016/j.biomaterials.2015.03.061.
- [21] Y. Matsumoto, N. Fukumitsu, H. Ishikawa, K. Nakai, and H. Sakurai, "A critical review of radiation therapy: From particle beam therapy (proton, carbon, and bnct) to beyond," *Journal of Personalized Medicine*, vol. 11, no. 8. MDPI, Aug. 01, 2021. doi: 10.3390/jpm11080825.
- [22] W. Sauerwein, A. Wittig, and R. Moss, "Neutron Capture Therapy: Principles and Applications," 2012.
- [23] E. M. Heber, M. F. Hawthorne, P. J. Kueffer, M. A. Garabalino, S. I. Thorp, "Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model," *Proc Natl Acad Sci U S A*, vol. 111, no. 45, pp. 16077–16081, Nov. 2014, doi: 10.1073/pnas.1410865111.
- [24] E. Meiyanto, H. Putri, Y. A. Larasati, and R. Fajarwati, "Pengembangan Boron Carrying Pharmaceuticals untuk Mendukung Terapi Kanker Berbasis BNCT."
- [25] R. F. Barth, M. G. Vicente, O. K. Harling, W. S. Kiger, K. J. Riley, "Current Status of Boron Neutron Capture Therapy of High Grade Gliomas and Recurrent Head and Neck Cancer," *Radiation Oncology*, vol. 7, no. 1, pp. 1–21, Aug. 2012, doi: 10.1186/1748-717X-7-146/TABLES/4.
- [26] IAEA, "Current Status of Neutron Capture Therapy," Vienna, 2001.
- [27] IAEA, *Cyclotron Produced Radionuclides: Principles and Practice*. Vienna: IAEA, 2008.
- [28] I. M. Ardana and Y. Sardjono, "Optimization of a Neutron Beam Shaping Assembly Design for BNCT and its Dosimetry Simulation Based on MCNPX," *Jurnal Teknologi Reaktor Kartini Tri Dasa Mega*, vol. 19, no. 3, p. 121, Oct. 2017, doi: 10.17146/tdm.2017.19.3.3582.
- [29] G. Li, W. Jiang, L. Zhang, W. Chen, and Q. Li, "Design of Beam Shaping Assemblies for Accelerator-Based BNCT With Multi-Terminals," *Front Public Health*, vol. 9, Mar. 2021, doi: 10.3389/fpubh.2021.642561.



- [30] Mobius Medical Systems, “Dose Volume Histogram Limits,” 2013.
- [31] B. Emami, “Tolerance of Normal Tissue to Therapeutic Radiation,” in *Reports of Radiotherapy and Oncology*, Department of Radiation Oncology, Loyola University Medical Center, 2013.
- [32] S. Bisello, S. Cilla, A. Benini, R. Cardano, N. P. Nguyen, “Dose–Volume Constraints for Organs at Risk in Radiotherapy (CORSAIR): An ‘All-in-One’ Multicenter–Multidisciplinary Practical Summary,” *Current Oncology*, vol. 29, no. 10. MDPI, pp. 7021–7050, Oct. 01, 2022. doi: 10.3390/curroncol29100552.
- [33] E. Topkan, A. Kucuk, E. Somay, B. Yilmaz, B. Pehlivan, and U. Sele, “Review of Osteoradionecrosis of the Jaw: Radiotherapy Modality, Technique, and Dose as Risk Factors,” *Journal of Clinical Medicine*, vol. 12, no. 8. MDPI, Apr. 01, 2023. doi: 10.3390/jcm12083025.
- [34] ICRP, “The 2007 Recommendations of the International Commission on Radiological Protection,” *ICRP Publication 103*, 2007.
- [35] ICRP, “Relative Biological Effectiveness (RBE), QualityFactor (Q), and Radiation Weighting Factor (wR),” *ICRP Publication 92*.
- [36] S. ichiro Masunaga, Y. Sakurai, H. Tanaka, K. Tano, M. Suzuki, “The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy,” *Springerplus*, vol. 3, no. 1, pp. 1–11, 2014, doi: 10.1186/2193-1801-3-128.
- [37] International Atomic Energy Agency, “Current Status of Neutron Capture Therapy,” Vienna, 2001.
- [38] K. Ono, “An analysis of the structure of the compound biological effectiveness factor,” in *Journal of Radiation Research*, Oxford University Press, Aug. 2016, pp. i83–i89. doi: 10.1093/jrr/rrw022.
- [39] M. Mu’alim, A. W. Harto, and Y. Sardjono, “Monte Carlo N Particle Extended (MCNPX) Radiation Shield Modelling on Boron Neutron Capture Therapy Facility Using D-D Neutron Generator 2.4 MeV,” 2019.
- [40] Judith F, “MCNP TM-A General Monte Carlo N-Particle Transport Code Version 4C.”
- [41] Z.-Y. Yang, P.-E. Tsai, S.-C. Lee, Y.-C. Chen, “Inter-comparison of Dose Distributions Calculated by FLUKA, GEANT4, MCNP, and PHITS for Proton Therapy.”



- [42] T. Sato, Y. Iwamoto, S. Hashimoto, T. Ogawa, “Features of Particle and Heavy Ion Transport code System (PHITS) version 3.02,” *J. Nucl. Sci. Technol*, 2018.
- [43] Y. H. Eun, W. E. Bolch, and K. F. Eckerman, “Revisions to the ornl series of adult and pediatric computational phantoms for use with the mird schema,” *Health Phys*, vol. 90, no. 4, pp. 337–356, Apr. 2006, doi: 10.1097/01.HP.0000192318.13190.c4.
- [44] Maria Droste Ratri Puspita, “Analisis Dosis Radiasi Terapi Kanker Serviks dengan Boron Neutron Capture Therapy (BNCT) Berbasis Particle and Heavy Ion Transport code System,” Universitas Gadjah Mada, 2021.
- [45] A. W. Lee, W. T. Ng, J. J. Pan, C. L. Chiang, S. S. Poh, H. C. Choi, “International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma,” *Int J Radiat Oncol Biol Phys*, vol. 105, no. 3, pp. 567–580, Nov. 2019, doi: 10.1016/j.ijrobp.2019.06.2540.
- [46] St. Stamford International Medical, “Nasopharyngeal Cancer Report.” <https://www.asiancancer.com/cancer-report/nasopharyngeal-cancer-report/> (accessed Mar. 05, 2023).
- [47] D. Eytan Keidar, D. Quynh-Nhu Vu, and Carl Shermetaro, “When Snoring isn’t just Snoring: Primary Nasopharyngeal Mantle Cell Lymphoma - A Rare Pathology in the Nasopharynx.,” *SMRJ*, vol. 4, no. 1, 2019.

